NewGenIvf Reports GAAP EPS of $96.76 and Revenue of $3.30 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: SeekingAlpha
Financial Performance: NewGenIvf reported a 9-month GAAP EPS of $96.76 and revenue of $3.30 million.
Market Expansion: The company has entered the art tokenization market with a $2 million deal.
Quant Rating: Seeking Alpha has provided a Quant Rating for NewGenIvf, indicating its performance metrics.
Historical Data: The press release includes historical earnings data and financial information for NewGenIvf.
Analyst Views on NIVF
About NIVF
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
